journal article·2024-08-12

Enhanced Stability of α-Mangostin-Rich Extract and Selective Cytotoxicity against Cancer Cells via Encapsulation in Antioxidant Nanoparticles (AME@NanoAOX)

Wiwit Suttithumsatid, Takuto Toriumi, Wanida Sukketsiri, Yukio Nagasaki, Pharkphoom Panichayupakaranant

Publisher page

Abstract

α-Mangostin-rich extract (AME) shows promise as a functional ingredient for cancer chemotherapy. Here, we encapsulated AME in our originally designed antioxidant nanoparticles (Nano AOX ) to increase its solubility and prevent oxidative degradation (AME@Nano AOX ). In this study, two types of self-assembled polymers containing nitroxide radicals were engineered. These polymers were self-assembled into nanoscale particles in aqueous media, entrapping AME (abbreviated as AME@Nano AOX (B) and AME@Nano AOX (G)). These formulations considerably improved the stability of AME against oxidative degradation and exhibited different release profiles of α-mangostin under different pH conditions. Furthermore, AME-encapsulated nanoparticles exhibited potent cytotoxicity against various cancer cell lines, including human breast cancer (MCF-7), human lung cancer (A549), human colon cancer (Caco-2), human cervical cancer (HeLa), and human liver cancer (HepG2) cell lines, with minimal cytotoxicity in normal human mammary epithelial cells (hTERT-HME1), thus providing a high selectivity index (SI). These results indicated the promising feature of AME-encapsulated antioxidant nanoparticles (AME@Nano AOX ) for cancer chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bioactive natural compounds · Bioactive Compounds and Antitumor Agents · Synthesis of Organic Compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai 90112, Thailand

Phytomedicine and Pharmaceutical Biotechnology Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai 90112, Thailand

Department of Materials Science, Faculty of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan

Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Songkhla, Hat-Yai 90112, Thailand

Department of Chemistry Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan

High-value Biomaterials Research and Commercialization Center (HBRCC), National Taipei University of Technology, Taipei 10608, Taiwan

Funding

Japan Society for the Promotion of Science

References (50)

Show source-provided references
1. 10.1200/GO.22.0042910.1200/GO.22.00429 ↗
2. 10.1016/j.actbio.2024.03.01910.1016/j.actbio.2024.03.019 ↗
3. 10.3390/ph1409083510.3390/ph14090835 ↗
4. 10.1007/s13659-020-00293-710.1007/s13659-020-00293-7 ↗
5. 10.1016/j.arabjc.2014.02.01110.1016/j.arabjc.2014.02.011 ↗
6. Wang J. J. · Anticancer Res. · 2012 · 32 · 3805
7. 10.1186/1476-4598-13-13810.1186/1476-4598-13-138 ↗
8. 10.1016/j.jff.2016.08.01410.1016/j.jff.2016.08.014 ↗
9. 10.1007/s12192-019-01063-210.1007/s12192-019-01063-2 ↗
10. 10.3389/fphar.2021.73965810.3389/fphar.2021.739658 ↗
11. 10.1186/s12885-022-09414-610.1186/s12885-022-09414-6 ↗
12. 10.13140/RG.2.2.23484.2624110.13140/RG.2.2.23484.26241 ↗
13. 10.3390/pharmaceutics1312199310.3390/pharmaceutics13121993 ↗
14. 10.1038/srep4271710.1038/srep42717 ↗
15. 10.1158/0008-5472.CAN-07-525910.1158/0008-5472.CAN-07-5259 ↗
16. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
17. 10.4103/2231-4040.10100610.4103/2231-4040.101006 ↗
18. 10.1039/C5BM00057B10.1039/C5BM00057B ↗
19. Vong L. B. · 2019 · 28710.1021/bk-2019-1309.ch012 ↗
20. 10.3390/jpm1102009210.3390/jpm11020092 ↗
21. 10.1016/j.jconrel.2015.04.02510.1016/j.jconrel.2015.04.025 ↗
22. 10.1002/adhm.20170042810.1002/adhm.201700428 ↗
23. 10.23880/ipcm-1600020110.23880/ipcm-16000201 ↗
24. 10.1002/adhm.20210006710.1002/adhm.202100067 ↗
25. 10.1016/j.biomaterials.2023.12205310.1016/j.biomaterials.2023.122053 ↗
26. 10.3390/polym1415313910.3390/polym14153139 ↗
27. 10.1155/2022/921726810.1155/2022/9217268 ↗
28. 10.1093/chromsci/47.3.18510.1093/chromsci/47.3.185 ↗
29. 10.14456/202203010310.14456/2022030103 ↗
30. 10.1177/1934578X2097455910.1177/1934578X20974559 ↗
31. 10.3390/cancers1206161610.3390/cancers12061616 ↗
32. 10.1186/1749-8546-7-1510.1186/1749-8546-7-15 ↗
33. 10.1186/1472-6882-10-5510.1186/1472-6882-10-55 ↗
34. 10.1055/s-0042-11965110.1055/s-0042-119651 ↗
35. 10.1016/j.lwt.2015.08.03610.1016/j.lwt.2015.08.036 ↗
36. 10.1016/j.heliyon.2019.e0246510.1016/j.heliyon.2019.e02465 ↗
37. 10.3390/molecules2604110910.3390/molecules26041109 ↗
38. 10.2147/NSA.S24301710.2147/NSA.S243017 ↗
39. 10.1016/j.tiv.2013.02.01910.1016/j.tiv.2013.02.019 ↗
40. 10.3109/1071576100366755410.3109/10715761003667554 ↗
41. 10.1016/j.jconrel.2013.08.01110.1016/j.jconrel.2013.08.011 ↗
42. 10.1016/j.biomaterials.2018.05.04210.1016/j.biomaterials.2018.05.042 ↗
43. 10.1016/j.biomaterials.2020.12029010.1016/j.biomaterials.2020.120290 ↗
44. 10.1016/j.jconrel.2022.04.00210.1016/j.jconrel.2022.04.002 ↗
45. 10.1088/1757-899X/1034/1/01213710.1088/1757-899X/1034/1/012137 ↗
46. 10.1016/j.biomaterials.2016.05.00110.1016/j.biomaterials.2016.05.001 ↗
47. 10.1016/j.cclet.2020.03.00110.1016/j.cclet.2020.03.001 ↗
48. 10.1016/j.addr.2011.09.00610.1016/j.addr.2011.09.006 ↗
49. 10.1016/j.polymer.2017.02.05210.1016/j.polymer.2017.02.052 ↗
50. 10.1039/c2bm00156j10.1039/c2bm00156j ↗